In order to meet the growing global demand for gene, cell and RNA therapies, Flash Therapeutics, a contract development and manufacturing organization (CDMO), is accelerating the ramp-up of its biomanufacturing capabilities. This will allow it to position itself for the production of large-scale clinical batches, including both integrative DNA and RNA technologies—proprietary LentiFlash technology.
 
This ambition requires an overall investment of around €15 million to ensure the growth of its production capacity to industrial level (GMP). In this context, Flash Therapeutics has signed a 3-year investment agreement of at least €15 million with TechLife Capital and Elaia Partners. The first tranche payment of €4 million made in July 2021 allows Flash Therapeutics to double its infrastructure over the next 12 months and to strengthen its commercial, process, analytical and production teams.
 
Flash Therapeutics’ strength and differentiator lies in its expertise in lentiviral transfer technologies (DNA and RNA) and its biomanufacturing process. The company offers a continuum of high purity vector manufacturing from research to clinical phases, accelerating therapeutic programs for its global customers—laboratories and biotechnology companies. Based in France, Flash Therapeutics is a key international, industrial partner for gene and cell therapy programs—genetic diseases, infectious diseases, cancers—and vaccination.
 
“This first tranche of €4 million in financing will allow us to continue the scale-up of biomanufacturing activities within Flash Therapeutics and to position ourselves for the launch of clinical batch manufacturing in 2025,” said Pascale Bouillé, president, Flash Therapeutics. “We will continue to develop our gene transfer technologies offering our customers innovative and differentiating tools, as well as to offer fast-growing production capacities. Our goal is to double in size by the second half of 2022 and to produce the first LentiFlash messenger RNA clinical batch by the end of 2022.”